Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance)
- Citation:
- Cancer Epidemiol Biomarkers Prev vol 30 (2) 404-411
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Parents:
- None
- Children:
- None
- Pharmas:
- Genentech, Sanofi, Pfizer, Eli Lilly and Company
- Grants:
- U10CA180821, U10CA180882, U24CA196171, R01CA176272, UG1CA233180, UG1CA233339, UG1CA189858, T32 CA094880, K05 CA152715
- Corr. Author:
- Authors:
- Julia D. Labadie Xinwei Hua Tabitha A. Harrison Barbara L. Banbury Jeroen R. Huyghe Wei Sun Qian Shi Greg Yothers Steven R. Alberts Frank A. Sinicrope Richard M. Goldberg Thomas J. George Kathryn L. Penney Amanda I. Phipps Stacey A. Cohen Ulrike Peters Andrew T. Chan Polly A. Newcomb
- Networks:
- LAPS-MN026, LAPS-OH007
- Study
- Alliance-A151904
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N0147
- Phases:
- N/A, 3
- Keywords:
- genetics, colon cancer, chemotherapy, rash